BofA raised the firm’s price target on Merck (MRK) to $120 from $105 and keeps a Buy rating on the shares. Merck shares look attractive as the pipeline has “rounded out,” says the analyst, who is shifting the firm’s valuation toward the firm’s new FY27 EPS estimate.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MRK:
- Merck & Company: Strong Growth Potential Amidst Robust Pipeline and Strategic Product Launches
- The Week That Was, The Week Ahead: Macro & Markets, Dec. 14
- Mixed options sentiment in Merck with shares up 0.71%
- Merck announces CHMP recommendation for expanded Winrevair indication
- Merck price target raised to $102 from $100 at Morgan Stanley